EGFR and non-small cell lung carcinoma: In pre-clinical models, HDAC inhibitors also have efficacy in EGFR-TKI drug-intolerant NSCLC cells caused by KDM5A upregulation [60], suggesting that HDAC inhibitors may have a role in overcoming particular types of EGFR-TKI resistance.